Low-dose vs. standard-dose alteplase for acute ischemic stroke: a retrospective cohort study of safety and efficacy in an Iranian population
Open Access
- 29 September 2025
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
Abstract
The optimal dosing of alteplase for acute ischemic stroke remains debated, particularly regarding the balance between efficacy and bleeding risks. This study compared outcomes between standard-dose (0.9 mg/kg) and low-dose (< 0.85 mg/kg) alteplase in an Iranian cohort. In this retrospective cohort study, 328 patients with acute ischemic stroke treated at Boo-Ali Sina Hospital (2016–2023) were analyzed. Participants were divided into standard-dose (n = 177) and low-dose (n = 151) groups. Primary outcomes included functional independence (modified Rankin Scale [mRS] 0–2 at 3 months) and symptomatic intracranial hemorrhage (sICH). Secondary outcomes comprised mortality and hemorrhagic complications. Multivariable logistic regression adjusted for age, NIHSS score, and comorbidities. The low-dose group had significantly lower rates of sICH (5.29% vs. 13.55%, p = 0.01), fatal bleeding (1.98% vs. 7.90%, p = 0.03), and in-hospital mortality (8.6% vs. 15.81%, p = 0.01). Parenchymal hemorrhage-1 occurred exclusively with standard dosing (15.9% vs. 0%). Three-month functional outcomes were comparable (mRS 0–2: 53.6% vs. 46.9%, p = 0.22). Adjusted analyses confirmed reduced odds of any ICH (OR 0.34, 95% CI 0.18–0.64) and fatal ICH (OR 0.23, 95% CI 0.06–0.83) with low-dose therapy. Low-dose alteplase was associated with fewer hemorrhagic complications and lower mortality while maintaining comparable functional outcomes to standard dosing. These findings support its potential as a safer alternative, particularly in resource-limited settings where cost and drug availability pose challenges. Randomized trials are needed to validate these results.Keywords
All Related Versions
Funding Information
- Mazandaran University of Medical Sciences
This publication has 37 references indexed in Scilit:
- Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-AnalysisJournal of Stroke and Cerebrovascular Diseases, 2018
- Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic StrokeJAMA Neurology, 2017
- Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic StrokeNew England Journal of Medicine, 2016
- Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in StrokeStroke, 2015
- Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 HoursStroke, 2015
- Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Stroke Is Better Than Low DosesStroke, 2014
- Different Doses of Recombinant Tissue-Type Plasminogen Activator for Acute Stroke in Chinese PatientsStroke, 2014
- Safety and efficacy of alteplase in the treatment of acute ischemic strokeVascular Health and Risk Management, 2009
- Aortic Atherosclerotic Disease and StrokeCirculation, 2006
- Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of OnsetStroke, 2006